Tuberculosis and HIV co-infection: a practical therapeutic approach (Q36688887)

15 August 2017

1 reference

title

Tuberculosis and HIV co-infection: a practical therapeutic approach (English)

1 reference

15 August 2017

0 references

Ronan A M Breen

1

1 reference

15 August 2017

Leonie Swaden

series ordinal

2

1 reference

15 August 2017

Jayne Ballinger

series ordinal

3

1 reference

15 August 2017

Marc C I Lipman

series ordinal

4

1 reference

15 August 2017

publication date

1 January 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

66

1 reference

15 August 2017

issue

18

1 reference

15 August 2017

page(s)

2299-2308

1 reference

Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666180-00003

Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666180-00003

Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666180-00003

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666180-00003

Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666180-00003

Pulmonary tuberculosis in AIDS patients: transient chest radiographic worsening after initiation of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666180-00003

Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666180-00003

Changing Clinical Presentation and Survival in HIV-Associated Tuberculosis After Highly Active Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666180-00003

Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa

21 January 2018

1 reference

12 December 2020

Increased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIV-infected individuals

1 reference

12 December 2020

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

1 reference

12 December 2020

Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis

1 reference

12 December 2020

Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis

1 reference

12 December 2020

The treatment of tuberculosis in HIV-infected persons.

1 reference

12 December 2020

Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens

1 reference

12 December 2020

Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis

1 reference

12 December 2020

Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group

1 reference

12 December 2020

The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fluoroquinolone use: potential pitfalls.

1 reference

12 December 2020

Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis

1 reference

12 December 2020

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis

1 reference

12 December 2020

Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1.

1 reference

12 December 2020

Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

1 reference

12 December 2020

A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis

1 reference

12 December 2020

Acquired immune deficiency in Haitians: opportunistic infections in previously healthy Haitian immigrants

1 reference

12 December 2020

Response to 'Does immune reconstitution promote active tuberculosis in patients receiving highly active antiretroviral therapy?' AIDS, 22 July 2005

1 reference

12 December 2020

A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads.

1 reference

12 December 2020

Hepatotoxicity of antiretrovirals: incidence, mechanisms and management

1 reference

12 December 2020

Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis

1 reference

12 December 2020

Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin

1 reference

12 December 2020

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005).

1 reference

12 December 2020

Fluoroquinolone Resistance in Patients with Newly Diagnosed Tuberculosis

1 reference

12 December 2020

Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin

1 reference

12 December 2020

Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis

1 reference

12 December 2020

The rise and fall of triple nucleoside reverse transcriptase inhibitor (NRTI) regimens

1 reference

12 December 2020

Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection

1 reference

12 December 2020

BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005.

1 reference

12 December 2020

Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy?

1 reference

12 December 2020

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

1 reference

12 December 2020

Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis

1 reference

12 December 2020

Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration

1 reference

12 December 2020

Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study

1 reference

12 December 2020

Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

1 reference

12 December 2020

How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control.

1 reference

12 December 2020

Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy

1 reference

12 December 2020

An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms.

1 reference

12 December 2020

Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients

1 reference

12 December 2020

The growing burden of tuberculosis: global trends and interactions with the HIV epidemic

1 reference

12 December 2020

Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide

1 reference

12 December 2020

Pharmacokinetic interactions with rifampicin : clinical relevance

1 reference

12 December 2020

Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results

1 reference

12 December 2020

Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium

1 reference

12 December 2020

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

1 reference

12 December 2020

Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia.

1 reference

12 December 2020

Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy

1 reference

12 December 2020

Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection

1 reference

12 December 2020

Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis

1 reference

12 December 2020

Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis

1 reference

12 December 2020

Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis

1 reference

12 December 2020

Prevention of lung infections associated with human immunodeficiency virus infection

1 reference

12 December 2020

Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons

1 reference

12 December 2020

Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy

1 reference

12 December 2020

Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment

1 reference

12 December 2020

The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India

1 reference

12 December 2020

Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis

1 reference

12 December 2020

WHO clinical staging of HIV infection and disease, tuberculosis and eligibility for antiretroviral treatment: relationship to CD4 lymphocyte counts.

1 reference

12 December 2020

The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis

1 reference

12 December 2020

Use of Standard Therapy for Tuberculosis is Associated with Increased Adverse Reactions in Patients with HIV

1 reference

12 December 2020

Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection

1 reference

12 December 2020

Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8.

1 reference

12 December 2020

Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy

1 reference

12 December 2020

Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana

1 reference

12 December 2020

Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis

1 reference

12 December 2020

Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society

1 reference

12 December 2020

Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden.

1 reference

12 December 2020

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis

1 reference

12 December 2020

A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection

1 reference

12 December 2020

Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all.

1 reference

12 December 2020

10.2165/00003495-200666180-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

15 August 2017

1038196008

0 references

1 reference